Corporate / M&A

Capital Markets

Molecular Partners

Homburger News

Share-Image Teamplate Deals-and-Cases

On October 25, 2024, Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics announced that it had priced an underwritten offering of 3,642,988 American Depositary Shares (ADSs) representing 3,642,988 new shares at an offering price of USD 5.49 per ADS amounting to gross proceeds of USD 20 m. The offering included participation from a new investor HBM Healthcare Investments Ltd, which is a leading healthcare investor, as well as multiple existing investors.
Molecular Partners currently intends to use the net proceeds from this offering for the development and expansion of its radiopharmaceutical pipeline and platform (Radio-DARPin Therapeutics) and other general corporate purposes.
The Homburger team was led by Dieter Gericke and Karin Mattle (both Corporate / M&amp;A, Capital Markets) and included Stefan Oesterhelt (Tax), Lorenzo Togni, Romain Fakhoury and Hans Glent Abildgaard (all Corporate / M&amp;A, Capital Markets).

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Employment and Executive Compensation

addex Therapeutics

Homburger advised Addex Therapeutics Ltd

On April 3, 2024, Addex Therapeutics, a clinical-stage biopharmaceutical company, listed on the SIX Swiss Exchange and on the Nasdaq, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
With initial funding of USD 63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix acquired a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex in view of accelerating their development. In return, Addex received CHF 5 million and a 20% equity interest in Neurosterix. Addex will retain its partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC, as well as unpartnered clinical stage assets including dipraglurant for Parkinson’s disease and post-stroke/TBI recovery as well as its preclinical GABAB positive allosteric modulator (PAM) program for chronic cough.
Homburger advised Addex in this transaction. The Homburger team comprised Frank Gerhard, Romain Fakhoury, Fabio Gasser, Paula Delissen (all Corporate / M&amp;A), Jeremy Reichlin (Employment) and Peter Müller (Tax).

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Nice-and-Green-web-640x140

On June 26, 2023, Evolva Holding SA announced that it had entered into a new agreement with Nice &amp; Green SA (N&amp;G) to replace an existing equity-linked debt instrument issued by Evolva consisting of convertible notes issued in several tranches to be drawn against issuance of convertible notes.
The new agreement now signed by Evolva and N&amp;G is expected to secure Evolva&#8217;s cash needs until the end of 2023, thereby allowing Evolva an orderly review of strategic alternatives. It consists of a financing line in the amount of up to CHF 12 m of which CHF 5.25 m can be drawn in 2023; additional drawings of up to 2.75 m in 2023 are subject to, among other things, N&amp;G’s ability to sell a certain volume of Evolva shares in the market. From January 1, 2024 onward, any further drawdown of the maximum commitment will be subject to additional conditions, in particular a minimum market capitalization threshold of Evolva of CHF 25 m and N&amp;G may terminate the agreement and request repayment in cash of any unconverted notes (stretched over five years on a quarterly pro rata basis) if such minimum market cap threshold is not met.
All newly issued or existing convertible notes are still mandatorily convertible into equity at the discretion of N&amp;G within a period of 24 months after their issuance or the date of the new agreement, respectively, with an unchanged conversion rate of 95% of the lowest volume-weighted average price during the six trading days preceding the conversion date.
Based in Nyon, Switzerland, N&amp;G is a private company which specializes in financing solutions tailored to the requirements of listed growth companies in the biotech and cleantech industries.
Homburger acts as legal advisor to N&amp;G in connection with the transaction. The Homburger team included Frank Gerhard, Timo Hasler and Romain Fakhoury (all Corporate / M&amp;A and Capital Markets).
&nbsp;

Homburger advises Nice & Green SA on the renegotiation of its investment in an equity-linked convertible notes debt instrument issued by Evolva Holding SA

Romain
Fakhoury

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Homburger advises Nice & Green SA on the renegotiation of its investment in an equity-linked convertible notes debt instrument issued by Evolva Holding SA

Aktienzusammenlegung (Reverse Stock Split) von börsenkotierten Schweizer Gesellschaften

Join the Team

Romain Fakhoury

Career

Languages

Bar Registration

Teams

RomainFakhoury

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Homburger advises Nice & Green SA on the renegotiation of its investment in an equity-linked convertible notes debt instrument issued by Evolva Holding SA

Aktienzusammenlegung (Reverse Stock Split) von börsenkotierten Schweizer Gesellschaften

Join the Team

Romain Fakhoury

Career

Languages

Bar Registration

Teams

Romain
Fakhoury